Evidence map›Paper›PMID 36919116›Full record

ArticleMolecular therapy. Nucleic acids2023

Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment.

Lingyue Yan, Yafei Su, Isaac Hsia, Ying Xu, Vui King Vincent-Chong, Wilfrido Mojica, Mukund Seshadri, Ruogang Zhao, Yun Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis.Journal of respiratory biology and translational medicine · 2025
    Article
  11. Review
  12. Review
  13. Effect of Transferrin-Modified FeThoracic cancer · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lingyue YanDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Yafei SuDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Isaac HsiaDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Ying XuDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Vui King Vincent-ChongDepartment of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Wilfrido MojicaDepartment of Pathology and Anatomical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Mukund SeshadriDepartment of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Ruogang ZhaoDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
Yun WuDepartment of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
University at Buffalo, State University of New York · USRoswell Park Comprehensive Cancer Center · US

Funding

Fibrotic microtissue chips for screening of anti-fibrotic therapiesR01EB019411 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI ZHAO, RUOGANG · 2015 to 2018
$1.4M
NIBIB NIH HHS R01 EB019411
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder with a low survival rate. Pulmonary fibrosis is one of the complications of COVID-19 and has a high prevalence in COVID-19 patients. Currently, no effective therapies other than lung transplantation are available to cure IPF and post-COVID-19 pulmonary fibrosis. MicroRNAs are small non-coding RNAs that mediate the development and progression of pulmonary fibrosis, thus making them potent drug candidates for this serious disease. MicroRNA-21 (miR-21) promotes not only the differentiation of fibroblasts to myofibroblasts but also epithelial-mesenchymal transition, both of which have been proposed as fundamental processes in pulmonary fibrosis development. Delivery of anti-miR-21 to block the miR-21-associated fibrogenic pathways represents a promising therapy for pulmonary fibrosis. However, microRNA treatment is challenged by quick degradation of RNA in blood, poor cellular uptake, and off-target effects. To overcome these challenges, we developed a lung-targeted, cationic liposome formulation to encapsulate anti-miR-21, enhance its delivery efficiency, and improve the therapeutic efficacy. We optimized the liposome formulation and demonstrated the anti-fibrotic effects using both

Indexed as

COVID-19drug deliveryliposomesmicroRNAmiR-21MT: Oligonucleotides: Therapies and Applicationspulmonary fibrosis

Identifiers

PMID36919116
PMCPMC9972768
OpenAlexW4322625623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.